APO Research
Talk to an analyst

APO RESEARCH · REPORT

Preventive Asthma Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Preventive Asthma Drug Market Outlook and Growth Opportunities 2026

19 December 2025198 pages

Choose your research edition.

Industry ResearchPreventive Asthma Drug Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Preventive Asthma Drug Industry Growth and Trends Forecast to 203294 pages · $3,450 USDMarket StructureGlobal Preventive Asthma Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032189 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Preventive Asthma Drug Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Preventive Asthma Drug Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Preventive Asthma Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Preventive Asthma Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Preventive Asthma Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Preventive Asthma Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Preventive Asthma Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Preventive Asthma Drug market include Callisto Pharmaceuticals, Molecular Insight Pharmaceuticals, Xiaflex, Roche and Novartis AG, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Preventive Asthma Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Preventive Asthma Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Preventive Asthma Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Preventive Asthma Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Preventive Asthma Drug Segment by Company

Callisto Pharmaceuticals

Molecular Insight Pharmaceuticals

Xiaflex

Roche

Novartis AG

Preventive Asthma Drug Segment by Type

Somatostatin Analogs

Chemotherapy

Targeted Therapy

Preventive Asthma Drug Segment by Application

Oncology Centres

Clinics

Hospital

Preventive Asthma Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Preventive Asthma Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Preventive Asthma Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Preventive Asthma Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Preventive Asthma Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Preventive Asthma Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Preventive Asthma Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Preventive Asthma Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Preventive Asthma Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Preventive Asthma Drug industry.

Chapter 3: Detailed analysis of Preventive Asthma Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Preventive Asthma Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Preventive Asthma Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Preventive Asthma Drug Industry Trends Table 2. Preventive Asthma Drug Industry Drivers Table 3. Preventive Asthma Drug Industry Opportunities and Challenges Table 4. Preventive Asthma Drug Industry Restraints Table 5. Global Preventive Asthma Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Preventive Asthma Drug Revenue Share by Company (2021-2026) Table 7. Global Preventive Asthma Drug Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Preventive Asthma Drug Sales Volume Share by Company (2021-2026) Table 9. Global Preventive Asthma Drug Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Preventive Asthma Drug Company Ranking, (2024-2026) & (USD Million) Table 11. Global Preventive Asthma Drug Key Company Manufacturing Base & Headquarters Table 12. Global Preventive Asthma Drug Company, Product Type & Application Table 13. Global Preventive Asthma Drug Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Preventive Asthma Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Somatostatin Analogs Table 18. Significant Companies of Chemotherapy Table 19. Significant Companies of Targeted Therapy Table 20. Global Preventive Asthma Drug Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 21. Global Preventive Asthma Drug Sales Volume by Type (2021-2026) & (K Units) Table 22. Global Preventive Asthma Drug Sales Volume by Type (2027-2032) & (K Units) Table 23. Global Preventive Asthma Drug Sales Volume Share by Type (2021-2026) Table 24. Global Preventive Asthma Drug Sales Volume Share by Type (2027-2032) Table 25. Global Preventive Asthma Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Preventive Asthma Drug Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Preventive Asthma Drug Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Preventive Asthma Drug Sales Value Share by Type (2021-2026) Table 29. Global Preventive Asthma Drug Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Oncology Centres Table 31. Significant Companies of Clinics Table 32. Significant Companies of Hospital Table 33. Global Preventive Asthma Drug Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 34. Global Preventive Asthma Drug Sales Volume by Application (2021-2026) & (K Units) Table 35. Global Preventive Asthma Drug Sales Volume by Application (2027-2032) & (K Units) Table 36. Global Preventive Asthma Drug Sales Volume Share by Application (2021-2026) Table 37. Global Preventive Asthma Drug Sales Volume Share by Application (2027-2032) Table 38. Global Preventive Asthma Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Preventive Asthma Drug Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Preventive Asthma Drug Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Preventive Asthma Drug Sales Value Share by Application (2021-2026) Table 42. Global Preventive Asthma Drug Sales Value Share by Application (2027-2032) Table 43. Global Preventive Asthma Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 44. Global Preventive Asthma Drug Sales by Region (2021-2026) & (K Units) Table 45. Global Preventive Asthma Drug Sales Market Share by Region (2021-2026) Table 46. Global Preventive Asthma Drug Sales by Region (2027-2032) & (K Units) Table 47. Global Preventive Asthma Drug Sales Market Share by Region (2027-2032) Table 48. Global Preventive Asthma Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Preventive Asthma Drug Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Preventive Asthma Drug Sales Value Share by Region (2021-2026) Table 51. Global Preventive Asthma Drug Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Preventive Asthma Drug Sales Value Share by Region (2027-2032) Table 53. Global Preventive Asthma Drug Market Average Price (US$/Unit) by Region (2021-2026) Table 54. Global Preventive Asthma Drug Market Average Price (US$/Unit) by Region (2027-2032) Table 55. Global Preventive Asthma Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Global Preventive Asthma Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Preventive Asthma Drug Sales by Country (2021-2026) & (K Units) Table 58. Global Preventive Asthma Drug Sales Market Share by Country (2021-2026) Table 59. Global Preventive Asthma Drug Sales by Country (2027-2032) & (K Units) Table 60. Global Preventive Asthma Drug Sales Market Share by Country (2027-2032) Table 61. Global Preventive Asthma Drug Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Preventive Asthma Drug Sales Value Market Share by Country (2021-2026) Table 63. Global Preventive Asthma Drug Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Preventive Asthma Drug Sales Value Market Share by Country (2027-2032) Table 65. Callisto Pharmaceuticals Company Information Table 66. Callisto Pharmaceuticals Business Overview Table 67. Callisto Pharmaceuticals Preventive Asthma Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 68. Callisto Pharmaceuticals Preventive Asthma Drug Product Portfolio Table 69. Callisto Pharmaceuticals Recent Development Table 70. Molecular Insight Pharmaceuticals Company Information Table 71. Molecular Insight Pharmaceuticals Business Overview Table 72. Molecular Insight Pharmaceuticals Preventive Asthma Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 73. Molecular Insight Pharmaceuticals Preventive Asthma Drug Product Portfolio Table 74. Molecular Insight Pharmaceuticals Recent Development Table 75. Xiaflex Company Information Table 76. Xiaflex Business Overview Table 77. Xiaflex Preventive Asthma Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 78. Xiaflex Preventive Asthma Drug Product Portfolio Table 79. Xiaflex Recent Development Table 80. Roche Company Information Table 81. Roche Business Overview Table 82. Roche Preventive Asthma Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 83. Roche Preventive Asthma Drug Product Portfolio Table 84. Roche Recent Development Table 85. Novartis AG Company Information Table 86. Novartis AG Business Overview Table 87. Novartis AG Preventive Asthma Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. Novartis AG Preventive Asthma Drug Product Portfolio Table 89. Novartis AG Recent Development Table 90. Key Raw Materials Table 91. Raw Materials Key Suppliers Table 92. Preventive Asthma Drug Distributors List Table 93. Preventive Asthma Drug Customers List Table 94. Research Programs/Design for This Report Table 95. Authors List of This Report Table 96. Secondary Sources Table 97. Primary Sources List of Figures Figure 1. Preventive Asthma Drug Product Image Figure 2. Global Preventive Asthma Drug Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Preventive Asthma Drug Sales Value (2021-2032) & (US$ Million) Figure 4. Global Preventive Asthma Drug Sales (2021-2032) & (K Units) Figure 5. Global Preventive Asthma Drug Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Preventive Asthma Drug Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Somatostatin Analogs Image Figure 10. Chemotherapy Image Figure 11. Targeted Therapy Image Figure 12. Global Preventive Asthma Drug Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 13. Global Preventive Asthma Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Preventive Asthma Drug Sales Volume Share by Type (2021-2032) Figure 15. Global Preventive Asthma Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Preventive Asthma Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Preventive Asthma Drug Sales Value Share by Type (2021-2032) Figure 18. Oncology Centres Image Figure 19. Clinics Image Figure 20. Hospital Image Figure 21. Global Preventive Asthma Drug Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global Preventive Asthma Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Preventive Asthma Drug Sales Volume Share by Application (2021-2032) Figure 24. Global Preventive Asthma Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Preventive Asthma Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Preventive Asthma Drug Sales Value Share by Application (2021-2032) Figure 27. Global Preventive Asthma Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 28. Global Preventive Asthma Drug Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Preventive Asthma Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Preventive Asthma Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Preventive Asthma Drug Sales Value (2021-2032) & (US$ Million) Figure 32. North America Preventive Asthma Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Preventive Asthma Drug Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Preventive Asthma Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Preventive Asthma Drug Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Preventive Asthma Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Preventive Asthma Drug Sales Value (2021-2032) & (US$ Million) Figure 38. South America Preventive Asthma Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Preventive Asthma Drug Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Preventive Asthma Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Preventive Asthma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Preventive Asthma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Preventive Asthma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Preventive Asthma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Preventive Asthma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Preventive Asthma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Preventive Asthma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Preventive Asthma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Preventive Asthma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Preventive Asthma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Preventive Asthma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Preventive Asthma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Preventive Asthma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Preventive Asthma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Preventive Asthma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Preventive Asthma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Preventive Asthma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Preventive Asthma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Preventive Asthma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Preventive Asthma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Preventive Asthma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Preventive Asthma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Preventive Asthma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Preventive Asthma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Preventive Asthma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Preventive Asthma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Preventive Asthma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Preventive Asthma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Preventive Asthma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Preventive Asthma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Preventive Asthma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Preventive Asthma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Preventive Asthma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Preventive Asthma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Preventive Asthma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Preventive Asthma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Preventive Asthma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Preventive Asthma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Preventive Asthma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Preventive Asthma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Preventive Asthma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Preventive Asthma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Preventive Asthma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Preventive Asthma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Preventive Asthma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Preventive Asthma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Preventive Asthma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Preventive Asthma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Preventive Asthma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Preventive Asthma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Preventive Asthma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Preventive Asthma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Preventive Asthma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Preventive Asthma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Preventive Asthma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Preventive Asthma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Preventive Asthma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Preventive Asthma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Preventive Asthma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Preventive Asthma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Preventive Asthma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Preventive Asthma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Preventive Asthma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Preventive Asthma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Preventive Asthma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Preventive Asthma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Preventive Asthma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Preventive Asthma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Preventive Asthma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Preventive Asthma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Preventive Asthma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Preventive Asthma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Preventive Asthma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Preventive Asthma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Preventive Asthma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Preventive Asthma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Preventive Asthma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Preventive Asthma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Preventive Asthma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Preventive Asthma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Preventive Asthma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Preventive Asthma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Preventive Asthma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Preventive Asthma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Preventive Asthma Drug Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Preventive Asthma Drug Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • Somatostatin Analogs
  • Chemotherapy
  • Targeted Therapy
Applications
  • Oncology Centres
  • Clinics
  • Hospital
Companies covered
  • Callisto Pharmaceuticals
  • Molecular Insight Pharmaceuticals
  • Xiaflex
  • Roche
  • Novartis AG

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Preventive Asthma Drug Sales Value (2021-2032)
  4. 1.2.2 Global Preventive Asthma Drug Sales Volume (2021-2032)
  5. 1.2.3 Global Preventive Asthma Drug Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Preventive Asthma Drug Market Dynamics
  1. 2.1 Preventive Asthma Drug Industry Trends
  2. 2.2 Preventive Asthma Drug Industry Drivers
  3. 2.3 Preventive Asthma Drug Industry Opportunities and Challenges
  4. 2.4 Preventive Asthma Drug Industry Restraints
3 Preventive Asthma Drug Market by Company
  1. 3.1 Global Preventive Asthma Drug Company Revenue Ranking in 2025
  2. 3.2 Global Preventive Asthma Drug Revenue by Company (2021-2026)
  3. 3.3 Global Preventive Asthma Drug Sales Volume by Company (2021-2026)
  4. 3.4 Global Preventive Asthma Drug Average Price by Company (2021-2026)
  5. 3.5 Global Preventive Asthma Drug Company Ranking (2024-2026)
  6. 3.6 Global Preventive Asthma Drug Company Manufacturing Base and Headquarters
  7. 3.7 Global Preventive Asthma Drug Company Product Type and Application
  8. 3.8 Global Preventive Asthma Drug Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Preventive Asthma Drug Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Preventive Asthma Drug Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Preventive Asthma Drug Market by Type
  1. 4.1 Preventive Asthma Drug Type Introduction
  2. 4.1.1 Somatostatin Analogs
  3. 4.1.2 Chemotherapy
  4. 4.1.3 Targeted Therapy
  5. 4.2 Global Preventive Asthma Drug Sales Volume by Type
  6. 4.2.1 Global Preventive Asthma Drug Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Preventive Asthma Drug Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Preventive Asthma Drug Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Preventive Asthma Drug Sales Value by Type
  10. 4.3.1 Global Preventive Asthma Drug Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Preventive Asthma Drug Sales Value by Type (2021-2032)
  12. 4.3.3 Global Preventive Asthma Drug Sales Value Share by Type (2021-2032)
5 Preventive Asthma Drug Market by Application
  1. 5.1 Preventive Asthma Drug Application Introduction
  2. 5.1.1 Oncology Centres
  3. 5.1.2 Clinics
  4. 5.1.3 Hospital
  5. 5.2 Global Preventive Asthma Drug Sales Volume by Application
  6. 5.2.1 Global Preventive Asthma Drug Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Preventive Asthma Drug Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Preventive Asthma Drug Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Preventive Asthma Drug Sales Value by Application
  10. 5.3.1 Global Preventive Asthma Drug Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Preventive Asthma Drug Sales Value by Application (2021-2032)
  12. 5.3.3 Global Preventive Asthma Drug Sales Value Share by Application (2021-2032)
6 Preventive Asthma Drug Regional Sales and Value Analysis
  1. 6.1 Global Preventive Asthma Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Preventive Asthma Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Preventive Asthma Drug Sales by Region: 2021-2026
  4. 6.2.2 Global Preventive Asthma Drug Sales by Region (2027-2032)
  5. 6.3 Global Preventive Asthma Drug Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Preventive Asthma Drug Sales Value by Region (2021-2032)
  7. 6.4.1 Global Preventive Asthma Drug Sales Value by Region: 2021-2026
  8. 6.4.2 Global Preventive Asthma Drug Sales Value by Region (2027-2032)
  9. 6.5 Global Preventive Asthma Drug Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Preventive Asthma Drug Sales Value (2021-2032)
  12. 6.6.2 North America Preventive Asthma Drug Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Preventive Asthma Drug Sales Value (2021-2032)
  15. 6.7.2 Europe Preventive Asthma Drug Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Preventive Asthma Drug Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Preventive Asthma Drug Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Preventive Asthma Drug Sales Value (2021-2032)
  21. 6.9.2 South America Preventive Asthma Drug Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Preventive Asthma Drug Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Preventive Asthma Drug Sales Value Share by Country, 2025 VS 2032
7 Preventive Asthma Drug Country-level Sales and Value Analysis
  1. 7.1 Global Preventive Asthma Drug Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Preventive Asthma Drug Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Preventive Asthma Drug Sales by Country (2021-2032)
  4. 7.3.1 Global Preventive Asthma Drug Sales by Country (2021-2026)
  5. 7.3.2 Global Preventive Asthma Drug Sales by Country (2027-2032)
  6. 7.4 Global Preventive Asthma Drug Sales Value by Country (2021-2032)
  7. 7.4.1 Global Preventive Asthma Drug Sales Value by Country (2021-2026)
  8. 7.4.2 Global Preventive Asthma Drug Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Preventive Asthma Drug Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Preventive Asthma Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Preventive Asthma Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Preventive Asthma Drug Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Preventive Asthma Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Preventive Asthma Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Preventive Asthma Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Preventive Asthma Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Preventive Asthma Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Preventive Asthma Drug Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Preventive Asthma Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Preventive Asthma Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Preventive Asthma Drug Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Preventive Asthma Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Preventive Asthma Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Preventive Asthma Drug Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Preventive Asthma Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Preventive Asthma Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Preventive Asthma Drug Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Preventive Asthma Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Preventive Asthma Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Preventive Asthma Drug Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Preventive Asthma Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Preventive Asthma Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Preventive Asthma Drug Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Preventive Asthma Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Preventive Asthma Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Preventive Asthma Drug Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Preventive Asthma Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Preventive Asthma Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Preventive Asthma Drug Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Preventive Asthma Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Preventive Asthma Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Preventive Asthma Drug Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Preventive Asthma Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Preventive Asthma Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Preventive Asthma Drug Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Preventive Asthma Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Preventive Asthma Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Preventive Asthma Drug Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Preventive Asthma Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Preventive Asthma Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Preventive Asthma Drug Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Preventive Asthma Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Preventive Asthma Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Preventive Asthma Drug Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Preventive Asthma Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Preventive Asthma Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Preventive Asthma Drug Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Preventive Asthma Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Preventive Asthma Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Preventive Asthma Drug Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Preventive Asthma Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Preventive Asthma Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Preventive Asthma Drug Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Preventive Asthma Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Preventive Asthma Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Preventive Asthma Drug Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Preventive Asthma Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Preventive Asthma Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Preventive Asthma Drug Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Preventive Asthma Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Preventive Asthma Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Preventive Asthma Drug Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Preventive Asthma Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Preventive Asthma Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Preventive Asthma Drug Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Preventive Asthma Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Preventive Asthma Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Preventive Asthma Drug Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Preventive Asthma Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Preventive Asthma Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Preventive Asthma Drug Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Preventive Asthma Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Preventive Asthma Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Preventive Asthma Drug Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Preventive Asthma Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Preventive Asthma Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Preventive Asthma Drug Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Preventive Asthma Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Preventive Asthma Drug Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Preventive Asthma Drug Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Preventive Asthma Drug Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Preventive Asthma Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Callisto Pharmaceuticals
  2. 8.1.1 Callisto Pharmaceuticals Company Information
  3. 8.1.2 Callisto Pharmaceuticals Business Overview
  4. 8.1.3 Callisto Pharmaceuticals Preventive Asthma Drug Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Callisto Pharmaceuticals Preventive Asthma Drug Product Portfolio
  6. 8.1.5 Callisto Pharmaceuticals Recent Developments
  7. 8.2 Molecular Insight Pharmaceuticals
  8. 8.2.1 Molecular Insight Pharmaceuticals Company Information
  9. 8.2.2 Molecular Insight Pharmaceuticals Business Overview
  10. 8.2.3 Molecular Insight Pharmaceuticals Preventive Asthma Drug Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Molecular Insight Pharmaceuticals Preventive Asthma Drug Product Portfolio
  12. 8.2.5 Molecular Insight Pharmaceuticals Recent Developments
  13. 8.3 Xiaflex
  14. 8.3.1 Xiaflex Company Information
  15. 8.3.2 Xiaflex Business Overview
  16. 8.3.3 Xiaflex Preventive Asthma Drug Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Xiaflex Preventive Asthma Drug Product Portfolio
  18. 8.3.5 Xiaflex Recent Developments
  19. 8.4 Roche
  20. 8.4.1 Roche Company Information
  21. 8.4.2 Roche Business Overview
  22. 8.4.3 Roche Preventive Asthma Drug Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Roche Preventive Asthma Drug Product Portfolio
  24. 8.4.5 Roche Recent Developments
  25. 8.5 Novartis AG
  26. 8.5.1 Novartis AG Company Information
  27. 8.5.2 Novartis AG Business Overview
  28. 8.5.3 Novartis AG Preventive Asthma Drug Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Novartis AG Preventive Asthma Drug Product Portfolio
  30. 8.5.5 Novartis AG Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Preventive Asthma Drug Value Chain Analysis
  2. 9.1.1 Preventive Asthma Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Preventive Asthma Drug Sales Mode & Process
  6. 9.2 Preventive Asthma Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Preventive Asthma Drug Distributors
  9. 9.2.3 Preventive Asthma Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst